Mexico gets China’s CanSino vaccine paperwork for approval News Staff

MEXICO CITY — Mexico announced Friday that the Chinese manufacturer of the CanSino vaccine has submitted paperwork for approval in Mexico.

Mexico is running out of vaccines, and has placed its hopes on CanSino’s single-shot dose. CanSino has carried out Phase 3 trials in Mexico with 14,425 volunteers enrolled. But the results of that trial and the estimated efficacy rate has not yet been revealed. Mexico would presumably require those figures for approval.

Foreign Relations Secretary Marcelo Ebrard wrote that the vaccine had been “applied successfully” in the trials, but did not release specific data.

Mexico has been promised 8 million doses of the CanSino vaccine by March, and is particularly upbeat about the Chinese shot because it is relatively easy to handle, and will be finished and bottled at a plant in Mexico.

Mexico also recently approved Russia’s Sputnik V vaccine, but won’t get that, or more doses of the Pfizer vaccine, until later this month.

Mexico has received only about 760,000 doses of the Pfizer vaccine, and has only about 89,000 of those left, many of which are earmarked for second shots. The country has been able to give doses to only about half its front-line medical personnel so far.

Mexico registered 13,757 confirmed infections Thursday, to reach 1.89 million so far. There were 1,682 deaths confirmed Thursday, for a total of almost 163,000.

Mexico City, the current epicenter of the pandemic in Mexico, remains under the highest level or alert with hospitals over 80% full. But on Friday, the city government announced that shopping centres would be allowed to reopen at 20% of capacity, as long as customers spent no longer than a half hour inside. It was not clear how that rule could be enforced.

The city’s beleaguered restaurants will be allowed to open three hours longer at night, but only in open-air terraces.

The Associated Press

Leave a Reply

Your email address will not be published. Required fields are marked *